Effect of emicizumab-neutralizing antibodies on activated partial thromboplastin time-based clotting time test results in patients treated with emicizumab

Novembrino, C; Boscolo-Anzoletti, M; Galbiati, E; Shinohara, S; Peyvandi, F

Peyvandi, F (通讯作者)，Univ Milan, Dept Pathophysiol & Transplantat, Via Pace 9, I-20122 Milan, Italy.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023; 7 (8):

Abstract

Background: Emicizumab is a bispecific humanized monoclonal antibody that shortens the activated partial thromboplastin time (aPTT), making aPTT-based......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索